Cystatin C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: Effect of treatment with B-vitamins

British Journal of Nutrition

Volumn 102, Issue 12, 2009, Pages 1783-1789

  Tobin, Kari Anne R ^a   Holven, Kirsten B ^b   Retterstol, Kjetil ^a   Strm, Ellen ^a   Ose, Leiv ^a   Aukrust, Pål ^a,b   Nenseter, Marit S ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Atherosclerosis; B vitamins; Cystatin C; Homocysteine; Inflammation

Indexed keywords

CYANOCOBALAMIN PLUS FOLIC ACID PLUS PYRIDOXINE; CYSTATIN C; MESSENGER RNA; PLACEBO; TRIOBE; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VITAMIN B GROUP; CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; MALE; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITAMIN SUPPLEMENTATION; BLOOD; CHEMISTRY; CROSS-SECTIONAL STUDY; DIET SUPPLEMENTATION; GENETICS; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; AGED; CROSS-SECTIONAL STUDIES; CYSTATIN C; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 74949115346     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114509991048     Document Type: Article

References (34)

1. Wald DS, Law M & Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-anal-ysis. BMJ 325, 1202-1206.
2. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015-2022.
3. Bautista LE, Arenas IA, Penuela A, et al. (2002) Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 55, 882-887.
4. Dayal S & Lentz SR (2008) Murine models of hyperhomocys-teinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 28, 1596-1605.
5. Toole JF, Malinow MR, Chambless LE, et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565-575.
6. Bønaa KH, Njølstad I, Ueland PM, et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578-1588.
7. Lonn E, Yusuf S, Arnold MJ, et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567-1577.
8. Yang Q, Botto LD, Erickson JD, et al. (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 1335-1343.
9. Wang X, Qin X, Demirtas H, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876-1882.
10. Spence JD (2006) Homocysteine. Call off the funeral. Stroke 37, 282-283.
11. Holven KB, Aukrust P, Holm T, et al. (2002) Folic acid treatment reduces chemokine release from peripheral blood mono-nuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 22, 699-703.
12. Holven KB, Aukrust P, Retterstøl K, et al. (2006) Increased levels of high-sensitivity C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 66, 45-54.
13. Holven KB, Halvorsen B, Bjerkeli V, et al. (2006) Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke 37, 1731-1736.
14. Arnadottir M, Hultberg B, Nilsson-Ehle P, et al. (1996) The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56, 41-46.
15. Lewerin C, Ljungman S & Nilsson-Ehle H (2007) Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. J Intern Med 261, 65-67.
16. Liu J, Sukhova GK, Sun JS, et al. (2004) Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24, 1359-1366.
17. Sukhova GK, Wang B, Libby P, et al. (2005) Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 96, 368-375.
18. Bengtsson E, Nilsson J & Jovinge S (2008) Cystatin C and cath-epsins in cardiovascular disease. Front Biosci 13, 5780-5786.
19. Shi GP, Sukhova GK, Grubb A, et al. (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104, 1191-1197.
20. Albert MA, Rifai N & Ridker PM (2001) Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 6, 145-149.
21. Djoussé L, Kurth T & Gaziano JM (2008) Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 155, 82-86.
22. Koenig W, Twardella D, Brenner H, et al. (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51, 321-327.
23. Ni L, Lü J, Hou LB, et al. (2007) Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 38, 3287-3288.
24. Maahs DM, Ogden LG, Kretowski A,et al. (2007) Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 56, 2774-2779.
25. Arpega°rd J, Ostergren J, de Faire U, et al. (2008) Cystatin C-a marker of peripheral atherosclerotic disease? Atherosclerosis 199, 397-401.
26. Bökenkamp A, Herget-Rosenthal S & Bökenkamp R (2008) Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 21, 1223-1230.
27. Nenseter MS, Ueland T, Retterstøl K, et al. (2009) Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects. Effect of treatment with B-vitamins. Stroke 40, 241-247.
28. Holven KB, Halvorsen B, Schulz H, et al. (2003) Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomo-cysteinaemic subjects. Eur J Clin Invest 33, 555-560.
29. Bengtsson E, To F, Grubb A, et al. (2005) Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180, 45-53.
30. Yap S, Boers GH, Wilcken B, et al. (2001) Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21, 2080-2085.
31. Keller C, Katz R, Cushman M, et al. (2008) Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9, 9.
32. Keller CR, Odden MC, Fried LF, et al. (2007) Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 71, 239-244.
33. Singh D, Whooley MA, Ix JH, et al. (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 22, 1087-1092.
34. Potter K, Hankey GJ, Green DJ, et al. (2008) Homocysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 28, 1158-1164.